Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
0.8500
-0.0700 (-7.61%)
At close: Jul 31, 2025, 4:00 PM
0.8843
+0.0343 (4.04%)
After-hours: Jul 31, 2025, 5:04 PM EDT

Company Description

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally.

The company’s flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted.

In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood.

The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010.

Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Cytosorbents Corporation
Cytosorbents logo
CountryUnited States
Founded1997
IndustryMedical Devices
SectorHealthcare
Employees149
CEOPhillip Chan

Contact Details

Address:
305 College Road East
Princeton, New Jersey 08540
United States
Phone732 329 8885
Websitecytosorbents.com

Stock Details

Ticker SymbolCTSO
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001175151
CUSIP Number23283X206
ISIN NumberUS23283X2062
Employer ID98-0373793
SIC Code3841

Key Executives

NamePosition
Dr. Phillip P. Chan M.D., Ph.D.Chief Executive Officer and Director
Vincent J. Capponi M.S.President and Chief Operating Officer
Peter J. Mariani CPAChief Financial Officer
Kathleen P. Bloch CPA, M.B.A.Advisor
Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D.Chief Medical Officer
Dr. Christian Steiner M.D.Executive Vice President of Sales and Marketing
Christopher Cramer M.B.A., M.S.Senior Vice President of Business Development
Jodi HooverExecutive
Dr. Robert H. Bartlett M.D.Co-Chairman of Cardiac Surgery Advisory Board and Consultant

Latest SEC Filings

DateTypeTitle
Jul 2, 20258-KCurrent Report
Jun 24, 20258-KCurrent Report
Jun 13, 20258-KCurrent Report
Jun 11, 20258-KCurrent Report
May 28, 2025SCHEDULE 13GFiling
May 14, 202510-QQuarterly Report
May 14, 20258-KCurrent Report
May 1, 20258-KCurrent Report
Apr 30, 2025SCHEDULE 13G/AFiling
Apr 23, 2025ARSFiling